Physician profile
Pamela Wang
NPI 1033188602
$4,006.46
in general payments reported to CMS, 2019-2025
37 companies · $989 in 2025
The $989 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $74.44 · 2021: $387 · 2022: $629 · 2023: $884 · 2024: $617 · 2025: $989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,440 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,439.68 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $641.80 | 2019-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $390.95 | 2019-2024 | Ubrelvy |
| Currax Pharmaceuticals LLC | $339.59 | 2023-2025 | Contrave, Nexletol, Onzetra Xsail |
| Novo Nordisk INC | $315.34 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $285.72 | 2023-2025 | Mounjaro |
| Eisai INC. | $239.02 | 2025 | |
| Pfizer INC. | $194.54 | 2023-2025 | |
| Therapeuticsmd, INC. | $176.77 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $135.53 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $109.83 | 2022 | |
| Glaxosmithkline, LLC. | $97.10 | 2021-2024 | Shingrix, Arexvy, Twinrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.46 | 2022-2024 | Jardiance |
| Astellas Pharma US INC | $88.33 | 2024-2025 | Veozah |
| Aimmune Therapeutics, INC. | $79.50 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $75.47 | 2021-2023 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.